Ion Beam (IBAB) | Stock Overview & Key Data
Ion Beam Applications S.A. | Mid-cap | Healthcare
Ion Beam Applications S.A. | Mid-cap | Healthcare
Ion Beam Performance Comparison
Stock Range
Today's Range
Low: €11.32
High: €11.50
on August 8, 2025
52 Week Range
Low: €9.40
High: €15.14
on April 7, 2025
on October 11, 2024
All-Time High: €56.94 on May 8, 2017
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€350.0M
EPS
0.31
P/E Ratio (TTM)
38.58
Forward P/E
11.96
P/B Ratio
3.16
PEG Ratio
11.96
Div. Yield
3.51%
ROE
8.52%
Beta
0.996
Debt to Equity
39.39
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
10.65%
Profit Margin
1.86%
Returns and Earnings
Return on Assets (TTM)
2.89%
Return on Equity (TTM)
8.52%
EBITDA
€24.2M
Net Income (TTM)
€9.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€17.07
Quarterly Revenue Growth (YoY)
-1.90%
Quarterly Earnings Growth (YoY)
7.70%
Dividend Information
Last 12-Month Dividend
€0.41
Current Dividend Yield
3.51%
3-Year Average Dividend Yield
1.46%
3-Year Average Annual Dividend
€0.27
3-Year Total Dividends
€0.81
Ex-Dividend Date
June 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ion Beam IBAB | 350.03M Mid-cap | -6.92% | -0.88% | 0.89% | -16.17% | -17.16% | -1.50% | -31.45% | 46.42% |
| Sequana Medical NV SEQUA | 87.33M Small-cap | 0.00% | -2.16% | 23.64% | -28.42% | -44.49% | 49.48% | -75.51% | -76.31% |
| Argenx SE ARGX | 36.23B Large-cap | -3.13% | 23.59% | 5.46% | -8.89% | -5.73% | 18.28% | 57.28% | 191.69% |
| UCB S.A UCB | 35.08B Large-cap | -3.12% | 8.59% | 17.93% | -2.51% | -3.58% | 15.99% | 149.93% | 78.52% |
| Fagron NV FAGR | 1.53B Large-cap | -5.06% | -6.35% | -2.36% | 5.57% | 23.21% | 8.12% | 49.10% | 8.34% |
| Nyxoah S.A NYXH | 246.76M Mid-cap | -1.52% | -3.85% | 16.28% | -37.20% | -24.42% | -19.33% | -39.34% | -67.90% |
Ownership & Short Interest
Insider Ownership
34.63%
Institutional Ownership
25.81%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
10K
Average 90-Day Volume
14K
Ion Beam Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ion Beam would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IBAB's 52-week high and low?
- In the last 52 weeks, Ion Beam reached a high of €15.14 (on October 11, 2024) and a low of €9.40 (on April 7, 2025).
- What is the market cap and P/E ratio for IBAB?
- Curious about Ion Beam's size and valuation? Its market capitalization stands at 350.03M. When it comes to valuation, the P/E ratio (trailing twelve months) is 38.58, and the forward P/E (looking ahead) is 11.96.
- Does IBAB pay dividends? If so, what's the yield?
- Yes, Ion Beam is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.51%, and the company has paid an average of €0.27 per share annually over the past 3 years.
- Who are Ion Beam's main competitors or similar companies to consider before investing?
When looking at Ion Beam, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sequana Medical NV
SEQUA87.33M Healthcare Medical Devices 49.48% -75.51% Argenx SE
ARGX36.23B Healthcare Biotechnology 18.28% 57.28% UCB S.A
UCB35.08B Healthcare Biotechnology 15.99% 149.93% Fagron NV
FAGR1.53B Healthcare Drug Manufacturers - Specialty & Generic 8.12% 49.10% Nyxoah S.A
NYXH246.76M Healthcare Medical Instruments & Supplies -19.33% -39.34% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ion Beam Applications S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Ion Beam's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 8.52%, the Debt to Equity ratio from the most recent quarter is 39.39, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IBAB?
- Looking at Ion Beam's growth, its revenue over the trailing twelve months (TTM) was €498M. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.90%, and quarterly earnings saw a YoY growth of 7.70%.
- How much of IBAB stock is held by insiders and institutions?
- Wondering who owns Ion Beam stock? Company insiders (like executives and directors) hold about 34.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 25.81%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.